Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials - 22/08/19
A. Blauvelt, Oregon Medical Research Center, Portland, OR; K. Reich, Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany; L. Spelman, Veracity Clinical Research, Brisbane, Australia and Probity Medical Research, Ontario, Canada; J. Bagel, Psoriasis Treatment Center of Central NJ, East Windsor, NJ; R. Bissonnette, Innovaderm Research, Montreal, QC, Canada; S. Gerdes, Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein – Kiel, Germany; S. Fakharzadeh, Janssen Scientific Affairs, LLC, Horsham, PA; M. Song, Janssen Research & Development, LLC, Spring House, PA; Y-K Shen, Janssen Research & Development, LLC, Spring House, PA; K. B. Gordon, Medical College of Wisconsin, Milwaukee, WI
Le texte complet de cet article est disponible en PDF. Supported 100% by Janssen Research & Development, LLC. |
Vol 81 - N° 4S1
P. AB38 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?